Targeted cancer therapy with gonadotropin-releasing hormone chimeric proteins

Expert Review of Anticancer Therapy

Volumn 4, Issue 1, 2004, Pages 151-161

  Ben Yehudah, Ahmi ^a   Lorberboum Galski, Haya ^a  

^a HEBREW UNIVERSITY   (Israel)

Author keywords

Apoptosis; Associated antigens; Cancer treatment; Chimeric proteins; Gonadotropin releasing hormone; Gonadotropin releasing hormone receptor; Tumor

Indexed keywords

BACTERIAL PROTEIN; CASPASE 3; CASPASE 9; CASPASE ACTIVATED DEOXYRIBONUCLEASE; CHIMERIC PROTEIN; CYTOTOXIC AGENT; DEOXYRIBONUCLEASE; DNA FRAGMENT; DOXORUBICIN; FAS LIGAND; GONADORELIN; GONADORELIN AGONIST; GONADORELIN ANTAGONIST; GONADORELIN ANTIBODY; GONADORELIN DERIVATIVE; GONADORELIN RECEPTOR; GONADORELIN[6 DEXTRO LYSINE] DOXORUBICIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN PE66; RITUXIMAB; TRASTUZUMAB; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; TUMOR VACCINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CANCER RESEARCH; CANCER THERAPY; CELL KILLING; CELL SURFACE; CLINICAL TRIAL; COLON ADENOCARCINOMA; DRUG BINDING SITE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG PROTEIN BINDING; DRUG TARGETING; GENE CONSTRUCT; GENE FUSION; GENE OVEREXPRESSION; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; MOLECULAR RECOGNITION; MOUSE; NONHUMAN; PANCREAS ISLET CELL CARCINOMA; RECEPTOR BINDING; REVIEW; TARGET CELL;

EID: 1142299483     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.4.1.151     Document Type: Review

References (56)

1. Stevanovic S. Identification of tumour-associated T-cell epitopes for vaccine development. Nature Rev. Cancer 2, 514-520 (2002).
2. Juretic A, Spagnoli GC, Schultz-Thater E, Sarcevic B. Cancer/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies. Lancet Oncol. 4, 104-109 (2003).
3. Renkvist N, Castelli C, Robbins PF, Parmiani G. A listing of human tumor antigens recognized by T-cells. Cancer Immunol. Immunother. 50, 3-15 (2001).
4. Engelhard VH, Bullock TN, Colella TA, Mullins DW. Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use. Cancer 6(Suppl. 3), S272-S280 (2000).
5. Schultze JL, Vonderheide RH. From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens. Trends Immunol. 22, 516-523 (2001).
6. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nature Rev. Cancer 2, 750-763 (2002).
7. Michael A, Pandha HS. Renal cell carcinoma: tumor markers, T-cell epitopes and potential for new therapies. Lancet Oncol. 4, 215-223 (2003).
8. Monzavi-Karbassi B, Cunto-Amesty G, Luo P, Kieber-Emmons T. Use of surrogate antigens as vaccines against cancer. Hybrid hybridomics 21, 103-109 (2002).
9. Brinkmann U, Pastan I. Immunotoxins against cancer. Biochem. Biophys. Acta 1198, 27-45 (1994).
10. Niv R, Cohen CJ, Denkberg G, Segal D, Reiter Y. Antibody engineering for targeted therapy of cancer: recombinant Fv-immunotoxins. Curr. Pharm. Biotechnol. 2, 19-46 (2001).
11. Reiter Y. Recombinant immunotoxins in targeted cancer cell therapy. Adv. Cancer Res. 81, 93-124 (2001).
12. Frankel AH. Bacterial and plant toxins-general mode of action. In: Chimeric Toxins: Mechanisms of action and Therapeutic Applications. Lorberboum-Galski H, Lazarovici P (Eds), Harwood Academic Publishers, NY, USA, 1-14 (2002).
13. Kreitman RJ. Chimeric fusion proteins-Pseudomonas exotoxin-based. Curr. Opin. Investig. Drugs 2, 1282-1293 (2001).
14. Ben-Yehudah A, Belostotsky R, Aqeilan R et al. Chimeric proteins: a novel approach for eliminating specific cell populations for targeted human therapy. In: Chimeric Proteins. Lorberboum-Gaiski H, Lazarovici P (Eds), Harwood Academic Publishers, NY, USA, 148-167 (2002).
15. Ben-Yehudah A, Belostotsky R. Lichtenstein M et al. Chimeric proteins as candidates for cancer treatment. Drugs Future 27, 851-861 (2002).
16. Huirne JA, Lambalk CB. Gonadotropin-releasing hormone receptor antagonists. Lancet 358, 1793-1803 (2001).
17. King JA, Millar RP. Evolutionary aspects of gonadotropin-releasing hormone and its receptor. Cell Mol. Neurobiol. 15, 5-23 (1995).
18. Neill JD. GnRH and GnRH receptor genes in the human genome. Endocrinology 143, 737-743 (2002).
19. 2+ responses in α T3-1 gonadotropes. J. Biol. Chem. 276, 3123-3129 (2001).
20. Hille B, Tse A, Tse FW, Bosma MM. Signaling mechanisms during the response of pituitary gonadotropes to GnRH. Recent Prog. Horm. Res. 50, 75-95 (1995).
21. Dubois EA, Zandbergen MA, Peute J, Goos HJ. Evolutionary development of three gonadotropin-releasing hormone (GnRH) systems in vertebrates. Brain Res. Bull. 57, 413-418 (2002).
22. Schally AV. Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides 20, 1247-1262 (1999).
23. Schally AV, Comaru-Schally AM, Nagy A et al. Hypothalamic hormones and cancer. Front Neuroendocrinol. 22, 248-291 (2001).
24. Schally AV, Nagy A. New approaches to treatment of various cancers based on cytotoxic analogs of LHRH, somatostatin and bombesin. Life Sci. 72, 2305-2320 (2003).
25. Sealfon SC, Weinstein H, Millar RP. Molecular mechanisms of ligand interaction with the gonadotropin-releasing hormone receptor. Endocr. Rev. 18, 180-205 (1997).
26. Boyle TA, Belt-Davis DI, Duello TM. Nucleotide sequence analyses predict that human pituitary and human placental gonadotropin-releasing hormone receptors have identical primary structures. Endocrine 9, 281-287 (1998).
27. Kakar SS, Grizzle WE, Neill JD. The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary. Mol. Cell. Endocrinol. 106, 145-149 (1994).
28. Grosse R, Schoneberg T, Schultz G, Gudermann T. Inhibition of gonadotropin-releasing hormone receptor signaling by expression of a splice variant of the human receptor. Mol. Endocrinol. 11, 1305-1318 (1997).
29. Kottler ML, Bergametti F, Carre MC et al. Tissue-specific pattern of variant transcripts of the human gonadotropin-releasing hormone receptor gene. Eur. J. Endocrinol. 140, 561-569 (1999).
30. Millar R, Lowe S, Conklin D et al. A novel mammalian receptor for the evolutionarily conserved Type II GnRH. Proc. Natl Acad. Sci. USA 98, 9636-9641 (2001).
31. Millar RP. GnRH II and Type II GnRH receptors. Trends Endocrinol. Metab. 14(1), 35-43 (2003).
32. Neill JD, Duck LW, Sellers JC, Musgrove LC. A gonadotropin-releasing hormone (GnRH) receptor specific for GnRH II in primates. Biochem. Biophys. Res. Commun. 282, 1012-1018 (2001).
33. Ben-Yehudah A, Lorberboum-Galski H. Are GnRH-based chimeric proteins the future targeting therapy for adenocarcinomas? Res. Trends 4, 49-59 (2001).
34. McArdle CA, Franklin J, Green L, Hislop JN. Signalling, cycling and desensitisation of gonadotrophin-releasing hormone receptors. J. Endocrinol. 173, 1-11 (2002).
35. McArdle CA, Franklin J, Green L, Hislop JN. The gonadotropin-releasing hormone receptor: signalling, cycling and desensitisation. Arch. Physiol. Biochem. 110, 113-122 (2002).
36. Hsu CT, Ting CY, Ting CJ et al. Vaccination against gonadotropin-releasing hormone (GnRH) using toxin receptor-binding domain-conjugated GnRH repeats. Cancer Res. 60, 3701-3705 (2000).
37. Nechushtan A, Yarkoni S, Marianovsky I, Lorberboum-Galski H. Adenocarcinoma cells are targeted by the new GnRH-PE66 chimeric toxin through specific gonadotropin-releasing hormone binding sites. J. Biol. Chem. 272, 11597-11603 (1997).
38. Ben-Yehudah A, Yarkoni S, Nechushtan A, Belostotsky R, Lorberbown-Galski H. Linker-based GnRH-PE chimeric proteins inhibit cancer growth in nude mice. Med. Oncol. 16, 38-45 (1999).
39. Schlick J, Dulieu P, Desvoyes B et al. Cytotoxic activity of a recombinant GnRH-PAP fusion toxin on human tumor cell lines. FEBS Lett. 472, 241-246 (2000).
40. Yang WH, Wieczorck M, Allen MC, Nett TM. Cytotoxic activity of gonadotropin-releasing hormone (GnRH)-pokeweed antiviral protein conjugates in cell lines expressing GnRH receptors. Endocrinology 144, 1456-1463 (2003).
41. Kreitman RJ. Immunotoxins in cancer therapy. Curr. Opin. Immunol. 11, 570-578 (1999).
42. Kreitman RJ. Immunotoxins. Expert Opin. Pharmacother. 1, 1117-1129 (2000).
43. Hengartner MO. The biochemistry of apoptosis. Nature 407, 770-776 (2000).
44. Zimmermann KC, Bonzon C, Green DR. The machinery of programmed cell death. Pharmacol. Ther. 92, 57-70 (2001).
45. Ravagnan I, Roumier T, Kroemer G. Mitochondria, the killer organelles and their weapons. J. Cell. Physiol. 192, 131-137 (2002).
46. Aqeilan R. Yarkoni S, Lorberboum-Galski H. Interleukin-2-Bax: a novel prototype of human chimeric proteins for targeted therapy. FEBS Lett. 457, 271-276 (1999).
47. Adams JM, Cory S. Life-or-death decisions by the Bcl-2 protein family. Trends Biochem. Sci. 26, 61-66 (2001).
48. Cory S, Adams JM. The Bcl2 family: regulators of the cellular life-or-death switch. Nature Rev. Cancer 2, 647-656 (2002).
49. Azar Y, Lorberboum-Galski H. GnRH-Bik/Bax/Bak chimeric proteins target and kill adenocarcinoma cells; the general use of proapoptotic proteins of the Bcl-2 family as novel killing components of targeting chimeric proteins. Apoptosis 5, 531-542 (2000).
50. Nagata S. Apoptotic DNA fragmentation. Exp. Cell Res. 256, 12-18 (2000).
51. Widlak P. The DFF40/CAD endonuclease and its role in apoptosis. Acta Biochem. Pol. 47, 1037-1044 (2000).
52. Ben-Yehudah A, Aqeilan R, Robashkevich D, Lorberboum-Galski H. Using apoptosis for targeted cancer therapy by a new gonadotropin releasing hormone-DNA fragmentation factor 40 chimeric protein. Clin. Cancer Res. 9, 1179-1190 (2003).
53. Ben-Yehudah A, Aqeilan R, Belostotsky R, Azar Y, Lorberboum-Galski H. Utilizing chimeric proteins for exploring the cellular fate of endogenous proteins. Biochem. Biopbys. Res. Commun. 290, 332-338 (2002).
54. Sion-Vardi N, Kaneti J, Segal-Abramson T et al. Gonadotropin-releasing hormone specific binding sites in normal and malignant renal tissue. J. Urol. 148, 1568-1570 (1992).
55. Morgan K, Conklin D, Pawson AJ et al. A Transcriptionally active human Type II gonadotropin-releasing hormone receptor gene homolog overlaps two genes in the antisense orientation on chromosome 1q.12. Endocrinology 144, 423-436 (2003).
56. Jemal A, Murray T, Samuels A et al. Cancer statistics, 2003. CA Cancer J. Clin. 53, 5-26 (2003).